RT Journal Article SR Electronic T1 The clinical value of SUV measurements in 99mTC-MDP SPECT/CT bone scans in the evaluation of therapy response in prostate cancer patients with bone metastases JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1789 OP 1789 VO 56 IS supplement 3 A1 Jin Lei Mao A1 Weihao Zhai A1 Richard Lewis A1 Wei He A1 Jerome Avondo A1 Marcus Hacker A1 Antti Sohlberg YR 2015 UL http://jnm.snmjournals.org/content/56/supplement_3/1789.abstract AB 1789 Objectives To evaluate the clinical value of SUV measurements in 99mTc methylene diphosphonate (9mTc MDP) SPECT/CT bone scans for assessing therapy response in prostate cancer and to investigate its relation with serum prostate-specific antigen (PSA), alkaline phosphatase (ALP), bone-specific alkaline phosphatase (BAP) and Gleason scores.Methods 312 patients with diagnosed prostate cancer were enrolled. All patients showed lumbar spine metastases based on the corresponding appearance on MRI. A 99mTc-MDP SPECT/CT bone scan, serum test of PSA, ALP, BAP and Gleason score were performed pre- and post- therapy. The SUV uptake in the bone scan was generated using the novel software ‘HERMES SUV-SPECT’. The quantitative results for pre- and post- therapy were divided into two groups according to PSA, ALP, BAP and Gleason score. The SPECT/CT SUV values (SUVmax by body weight) were compared with these two groups using multivariate analysis.Results The measured SUV values were 35.1±6.80 for 435 lumbar vertebral lesions in the pre-therapy scans. 625 patients with normal lumbar vertebrae were measured to be 8.50±1.80. The difference was statistically significant (P<0.001). Multivariate analysis suggested that the difference in pre- and post- therapy SUV lesion measurements demonstrated a statistically significant difference in the group of PSA >50ug/ml, ALP>1000ug/L, BAP >20.1ug/L and Gleason score7-10 points. There was no statistically significant difference (P> 0.05) of pre- and post- therapy SUV values in the group whose PSA <25ug/ml, ALP>350ug/L , BAP <20ug/L. Gleason score was less than 7 points.Conclusions The software ‘SUV-SPECT’ is a user-friendly, reliable and robust quantification tool. SUV measurements of SPECT/CT bone scans can be an absolute quantification to follow-up prostate patients with bone metastases in daily clinical practice.